NDC product
PedvaxHIB
NDC 0006-4897 · Merck Sharp & Dohme LLC
Key facts
| Product NDC | 0006-4897 |
|---|---|
| Proprietary name | PedvaxHIB |
| Nonproprietary name | Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) |
| Substances | HAEMOPHILUS INFLUENZAE TYPE B CAPSULAR POLYSACCHARIDE MENINGOCOCCAL OUTER MEMBRANE PROTEIN CONJUGATE ANTIGEN |
| Dosage form | INJECTION, SUSPENSION |
| Route | INTRAMUSCULAR |
| Labeler | Merck Sharp & Dohme LLC |
| Product type | VACCINE |
| Marketing category | BLA |
| Application number | BLA103237 |
| Pharmacologic classes | Actively Acquired Immunity [PE], Haemophilus Vaccines [CS], Inactivated Haemophilus Influenzae B Vaccine [EPC], Vaccines, Inactivated [CS] |
| Marketing start | Dec 20, 1989 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: